Cogent Biosciences (COGT) released detailed PEAK Phase 3 data for its bezuclastinib and sunitinib combination in imatinib-treated GIST, alongside FDA Priority Review and the launch of a new first-line trial.
See our latest analysis for Cogent Biosciences.
The US$34.81 share price has been volatile, with the stock up 6.55% over 7 days but down 4.97% over 30 days. The 1 year total shareholder return is about 6x, indicating strong momentum built over the past year that contrasts with more recent consolidation around the latest PEAK data and FDA Priority Review news.
If the bezuclastinib story has your attention, it can be useful to see what else is advancing in the sector, including 40 healthcare AI stocks
With Cogent now valued at about…
